contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-navigates-its-way-to-the-united-arab-emirates

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

In the post-pitch Q&A, it was mentioned that with that 25 million, Phase 3 can be completed and the product further developed, but commercializing the product will then require more money. Then it’s a separate question what Sinaptica’s plans are after a successful Phase 3. One option is to raise money and start commercializing themselves, but another option is also to sell the company at that stage to a larger player who handles the commercialization.

According to Mariash, a 25 million round is open, and that should be enough to reach a finished product. It feels like a remarkably cost-effective study to get all the way to FDA approval. Is there a place to see the details of these funding rounds?

Looking through rose-tinted glasses: I wonder if a backlog for NBS6 sales has already built up in the UAE, which Brainlab can now start clearing? In my previous job, I dealt with customers from that region to some extent, and there is a very strong phenomenon where you have to get the same (but double the amount) for your own turf as your neighbor. The actual need for the acquisition is usually considered later. I don’t believe private clinics are any different in this regard. Now, let’s just get those “sixes” to the desert by the containerload

Here are Antti’s comments on how Nexstim received marketing authorization for its latest generation NBS 6 diagnostic equipment in the United Arab Emirates.                    Inderes              Nexstim navigoi tiensä Arabiemiirikuntiin - Inderes    NBS 6 -laitteiston myyntilupa Arabiemiirikunnissa avaa uuden markkinan ja tukee ennusteitamme tulevasta kasvusta.

Where can this information be found? The message must be at least 50 characters long.

With the new approval, the amount of Brainlab’s guaranteed sales margin will also increase.

Nexstim

The marketing authorization for the NBS 6 system in the United Arab Emirates opens up a new market and supports our estimates for future growth.

Translation: Original published in Finnish on 02/17/2026 at 07:35 am EET
On Monday, Nexstim announced it had received marketing authorization for its latest generation NBS 6 diagnostic system in the United Arab Emirates. The news represents a step forward in the company&apos;s gradual international expansion, which in turn supports our estimates for the company&apos;s growth in the coming years.
International availability of the NBS 6 system expands
NBS 6 is Nexstim&#x2019;s latest, modular system generation, which the company has designed to be more user-friendly and flexible than before. The system&apos;s diagnostic features received regulatory approvals in Europe and the US at the end of 2025, and the UAE marketing authorization supports the company&apos;s geographical expansion. Nexstim already received marketing authorizations for the therapy features of the system in 2023. The diagnostics business is Nexstim&apos;s traditional strength, and NBS 6 is currently the only FDA-approved and CE-marked navigated TMS system used for pre-surgical mapping of the brain&apos;s speech and motor cortices.
Nexstim has entered into a cooperation agreement with Brainlab for the sale and distribution of diagnostic equipment. The marketing authorization received by Nexstim enables the sale of the system in a new market, where, in our estimation, Brainlab is responsible for the actual sales efforts.

	2024	25e	26e
Revenue	8.7	12.3	15.2
growth-%	20.5 %	41.1 %	23.4 %
EBIT (adj.)	-0.5	1.5	2.7
EBIT-% (adj.)	-6.1 %	11.8 %	17.8 %
EPS (adj.)	-0.12	0.17	0.35
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	65.5	32.7
EV/EBITDA	189.9	35.9	21.0

Nexstim navigates its way to the United Arab Emirates

Key Estimate Figures04.01

Forum discussions